The UroLift® System for Benign Prostatic
Hyperplasia (BPH) is being showcased at the professional Barcelona-held
urology event from tomorrow (March 15-19) on Booth F43. A poster
presentation at Green Area, Room 20, will highlight the use of the
treatment in men with catheter dependent urinary retention.
WAYNE, Pa.--(BUSINESS WIRE)--Mar. 14, 2019--
Teleflex Incorporated (NYSE:TFX) today announced a Poster Presentation
highlighting its UroLift® System treatment at this
year’s European Association of Urology meeting as the company plans to
build upon the success of its novel UroLift® System for
patients with Benign Prostatic Hyperplasia (BPH).
The Poster, by Dr. Thomas Mueller, of New Jersey Urology, Sewell, U.S.,
is entitled Pulling The Foley:Can the Prostatic Urethral Lift
be used in men with catheter-dependent urinary retention? It will be
presented on Monday 18 March 14.00 to 15:30 at Green Area, Room 20.
EMEA General Manager, Interventional Urology, Mr. Matt Wiggins, said: “I
am looking forward to meeting urologist colleagues old and new in
Barcelona to discuss our plans to extend our footprint across EMEA and
build upon the rapid uptake of the UroLift System that we’ve experienced
in the UK.“
Last year, the UroLift System was acknowledged as a transformative
technology within the UK public healthcare system, as one of the small
handful of technologies selected by the UK Government as an Accelerated
Access Collaborative “Rapid Uptake Product”. This enables transformative
products to reach patients as quickly as possible through streamlined
regulatory and market access decisions.
The UroLift System is the only BPH treatment option shown to not cause
new onset, sustained erectile or ejaculatory dysfunction.*1-5
It is a minimally invasive, true day case procedure; which can be
performed under local anesthesia; offers a rapid improvement in symptoms
and a return to normal activity within days – usually without the need
to be discharged with the inconvenience and discomfort of a catheter.”1,6
About the UroLift® System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function.*1,5 Patients also experienced a significant
improvement in quality of life. Over 100,000 men have been treated with
the UroLift System in the U.S. Most common adverse events reported
include hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The Prostatic
Urethral Lift procedure using the UroLift System is recommended for the
treatment of BPH in both the American Urological Association and
European Association of Urology clinical guidelines. The UroLift System
is available in the U.S., Europe, Australia, Canada, Mexico and South
Korea. Learn more at www.UroLift.com.
About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our initial
focus is on improving the standard of care for patients with BPH using
the UroLift System, a minimally invasive permanent implant system that
treats symptoms while preserving normal sexual function. *1,5
Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch®, UroLift® System and Weck® – trusted brands united by a common
sense of purpose.
References:
*No instances of new, sustained erectile or ejaculatory
dysfunction
1. L.I.F.T. IDE Study. Roehrborn. J Urology 2013
2.
AUA BPH Guidelines 2003, 2010, 2018
3. Naspro, Eur Urol 2009
4.
Montorsi, J Urol 2008
5. McVary, J Sex Med 2016
6. Shore, Can
J Urol 2014
MAC00981-01 Rev A
View source version on businesswire.com: https://www.businesswire.com/news/home/20190314005040/en/
Source: Teleflex
Teleflex Incorporated:
Jake Elguicze
Treasurer and Vice
President, Investor Relations
001 610.948.2836
Media:
Gloucester Road Communications
Amanda Hayhurst
0044
772 0205581